Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326221 · ClinicalTrials.gov registry record
Single Dose Truvada in HIV-negative Men and Women
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 12
- Enrollment target
NCT01326221 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 12 participants.
The verdict
NCT01326221 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This open-label, non-blinded, pharmacokinetic (PK) study will assess both tenofovir and emtricitabine (components of Truvada) concentrations within genital tract of male and females after a single dose of Truvada®. Concentrations of the active drug will be measured in blood (women and men), cervicovaginal aspirates and vaginal tissue (women only), seminal fluid and rectal tissue (men only). Samples will be obtained at 24 hours (1 day), 48 hours (2 days), 5 days, 7 days, 10 days, and 14 days post-dose. Each subject will undergo 2 biopsy days, at least 72 hours apart. Additionally, tissue samples will be evaluated ex-vivo for HIV infectivity.
Interventions
- DRUG tenofovir + emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326221
The ClinicalTrials.gov registry entry for NCT01326221 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tenofovir + emtricitabine is the first listed.
NCT01326221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326221 about?
NCT01326221 is a clinical study titled "Single Dose Truvada in HIV-negative Men and Women". This open-label, non-blinded, pharmacokinetic (PK) study will assess both tenofovir and emtricitabine (components of Truvada) concentrations within genital tract of male and females after a single dose of Truvada®. Concentrations of the active drug will be measured in blood (women and men), cervicov...
What is the current status of trial NCT01326221?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2008-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT01326221?
The interventions under investigation include: tenofovir + emtricitabine (DRUG).
Who is sponsoring clinical trial NCT01326221?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.